PDCD1 and neoplasm: In two published models where anti–PD-L1 or anti–PD-1 had some effect alone, EVs were shown to synergize with checkpoint blockade in a therapeutic model, indicating that an immunogenic tumor will also respond more easily to combination therapy (45, 46).